Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells

Nature Genetics

Volumn 34, Issue 1, 2003, Pages 85-90

  Cheok, Meyling H ^a,b   Yang, Wenjian ^a   Pui, Ching Hon ^a,c   Downing, James R ^a   Cheng, Cheng ^a   Naeve, Clayton W ^a   Relling, Mary V ^a,c   Evans, William E ^a,c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MERCAPTOPURINE; METHOTREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL CYCLE; CONTROLLED STUDY; DRUG RESPONSE; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LYMPHATIC LEUKEMIA; MAJOR CLINICAL STUDY; MISMATCH REPAIR; MITOSIS RATE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; STRESS;

6-MERCAPTOPURINE; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; METHOTREXATE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TUMOR CELLS, CULTURED;

EID: 0037738513     PISSN: 10614036     EISSN: None     Source Type: Journal    
DOI: 10.1038/ng1151     Document Type: Article

References (29)

1. Pui, C.H. & Evans, W.E. Acute lymphoblastic leukemia. N. Engl. J. Med. 339, 605-615 (1998).
2. Evans, W.E. & Relling, M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487-491 (1999).
3. Evans, W.E. & McLeod, H.L. Pharmacogenomics - drug disposition, drug targets, and side effects. N. Engl. J. Med. 348, 538-549 (2003).
4. Pui, C.H., Campana, D. & Evans, W.E. Childhood acute lymphoblastic leukaemia - current status and future perspectives. Lancet Oncol. 2, 597-607 (2001).
5. Golub, T.R. et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286, 531-537 (1999).
6. Armstrong, S.A. et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat. Genet. 30, 41-47 (2002).
7. Ferrando, A.A. et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 1, 75-87 (2002).
8. Yeoh, E.-J. et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1, 133-143 (2002).
9. Scherf, U. et al. A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 24, 236-244 (2000).
10. Tsurusawa, M., Saeki, K. & Fujimoto, T. Differential induction of apoptosis on human lymphoblastic leukemia Nalm-6 and Molt-4 cells by various antitumor drugs. Int. J. Hematol. 66, 79-88 (1997).
11. Elion, G.B. The purine path to chemotherapy. Science 244, 41-47 (1989).
12. Ashburner, M. et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 25, 25-29 (2000).
13. Kastan, M.B. & Lim, D.S. The many substrates and functions of ATM. Nat. Rev. Mol. Cell Biol. 1, 179-186 (2000).
14. Baskaran, R. et al. Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. Nature 387, 516-519 (1997).
15. Li, J.C. & Kaminskas, E. Accumulation of DNA strand breaks and methotrexate cytotoxicity. Proc. Natl. Acad. Sci. USA 81, 5694-5698 (1984).
16. Lorico, A. et al. Accumulation of DNA strand breaks in cells exposed to methotrexate or N10-propargyl-5,8-dideazafolic acid. Cancer Res. 48, 2036-2041 (1988).
17. Nelson, W.G. & Kastan, M.B. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell Biol. 14, 1815-1823 (1994).
18. Bakkenist, C.J. & Kastan, M.B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421, 499-506 (2003).
19. Wijnen, J. et al. Majority of hMLH1 mutations responsible for hereditary nonpolyposis colorectal cancer cluster at the exonic region 15-16. Am. J. Hum. Genet. 58, 300-307 (1996).
20. Palmirotta, R. et al. Transcripts with splicings of exons 15 and 16 of the hMLH1 gene in normal lymphocytes: implications in RNA-based mutation screening of hereditary non-polyposis colorectal cancer. Eur. J. Cancer 34, 927-930 (1998).
21. Gong, J.G. et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 399, 806-809 (1999).
22. Swann, P.F. et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 273, 1109-1111 (1996).
23. Marton, M.J. et al. Drug target validation and identification of secondary drug target effects using DNA microarrays. Nat. Med. 4, 1293-1301 (1998).
24. Sotiriou, C. et al. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res. 4, R3 (2002).
25. Bokkerink, J.R et al. 6-Mercaptopurine: cytotoxicity and biochemical pharmacology in human malignant T-lymphoblasts. Biochem. Pharmacol. 45, 1455-1463 (1993).
26. Gorlick, R. et al. Intrinsic and acquired resistance to methotrexate in acute leukemia. N. Engl. J. Med. 335, 1041-1048 (1996).
27. Masson, E. et al. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J. Clin. Invest. 97, 73-80 (1996).
28. Synold, T.W. et al. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J. Clin. Invest. 94, 1996-2001 (1994).
29. Lipshutz, R.J., Fodor, S.P., Gingeras, T.R. & Lockhart, D.J. High density synthetic oligonucleotide arrays. Nat. Genet. 21, 20-24 (1999).